AACE/ADA Consensus Statement
Etie S. Moghissi(University of California, Los Angeles), Guillermo E. Umpierrez(Emory University), Irl B. Hirsch(University of Washington), Mary T. Korytkowski(University of Pittsburgh), M. Sue Kirkman(American Diabetes Association), Faramarz Ismail‐Beigi(Case Western Reserve University), Richard Hellman(American Association of Clinical Endocrinologists), Silvio E. Inzucchi(Yale University), Daniel Einhorn(Diabetes & Endocrine Associates), Monica M. DiNardo(University of Pittsburgh)
Cited by 516
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
|Diabetes Care|2012|3.2k
Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes
|The Journal of Clinical Endocrinology & Metabolism|2002|2.1k